SEARCH

SEARCH BY CITATION

References

  • 1
    Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 22847.
  • 2
    Piessevaux H, Buyse M, De Roock W et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol 2009; 20: 137582.
  • 3
    Piessevaux H, Schlichting M, Heeger S, Van Cutsem EST. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (mCRC): analysis from the CRYSTAL study. Abstracts of the 35th European Society for Medical Oncology Conference. October 8–12, 2010. Milan, Italy. Ann Oncol. 2010; 21(Suppl 8): viii 189viii 224.
  • 4
    Piessevaux H, Van Cutsem E, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Early tumor shrinkage and clinical outcome in metastatic colorectal cancer: Analysis of predictive utility in the CRYSTAL and OPUS studies. Oral presentation at the 10th Annual Meeting of the Japanese Society of Medical Oncology (JSMO), Osaka July 28th. 2012.
  • 5
    Glimelius B, Sorbye H, Balteskard L et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008; 19: 90914.
  • 6
    Suzuki C, Blomqvist L, Sundin A et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 2012; 23: 94854.
  • 7
    Fischer von Weikersthal L, Schalhorn A, Stauch M et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011; 47: 20614.
  • 8
    Hunter RD. WHO Handbook for Reporting Results of Cancer Treatment. Int J Radiat Biol 1980; 38: 481.
  • 9
    Grothey A, Hedrick EE, Mass RD et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008; 26: 1839.
  • 10
    Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 2330.
  • 11
    Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 233542.
  • 12
    Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356: 3738.
  • 13
    Methy N, Bedenne L, Bonnetain F. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists BMC Cancer 2010; 10: 277.
  • 14
    Piessevaux H, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: lessons from the OPUS trial. ASCO Meeting Abstracts 2011; 29(Suppl 4): 398.
  • 15
    Piessevaux H, Van Cutsem E, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies. ASCO Meeting Abstracts 2011; 29(Suppl 15): 3572.
  • 16
    Modest DP, Laubender RP, Stintzing S et al. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol 2012. Epub ahead of print.
  • 17
    Mansmann UR, Laubender RP, Giessen CA, Sartorius U, Heinemann V. Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2012; 30(Suppl 4): 580.
  • 18
    Fleming TR. Objective response rate as a surrogate end point: a commentary. J Clin Oncol 2005; 23: 48456.
  • 19
    Claret L, Girard P, Hoff PM et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009; 27: 41038.
  • 20
    Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 71019.